Skip to main content

Advertisement

Table 2 Persons with dementia not otherwise specified (DNOS) living at home

From: Prevalence of dementia diagnoses not otherwise specified in eight European countries: a cross-sectional cohort study

  Sweden n = 8 Finland n = 1 The NL n = 58 Germany n = 52 Estonia n = 42 France n = 4 Spain n = 16 The UK n = 12
Persons with DNOS, n (%) (total n = 193) 8 (4) 1 (1) 58 (30) 52 (26) 42 (21) 4 (2) 16 (8) 12 (6)
 Age, years; mean (SD) 86 (6) 89 (0) 82 (6) 84 (6) 83 (9) 84 (4) 90 (7) 84 (6)
 Gender, female (%) 6 (75) 0 (0) 32 (55) 37 (71) 31 (74) 3 (75) 13 (81) 6 (50)
 Symptoms, years, mean (SD) 3.6 (3.7) 3 (3) 4.4 (2.7) 5.1 (3.6) 5.8 (5.0) 0.3 (0.5) 3.5 (2.1) 4.0 (3.6)
Comorbidity (CCI), 0–37, mean, (SD) 2.1 (1.2) 2.0 (0) 2.0 (1.3) 2.8 (1.6) 2.6 (1.6) 2.3 (1.9) 2.6 (1.3) 1.9 (0.9)
Cognitive function (SMMSE), 0–30 20 (2) 23 (0) 14 (6) 13 (8) 12 (6) 14 (7) 14 (7) 17 (6)
Quality of life (QoL-AD), 13–52 36 (5) 27 (0) 35 (5) 35 (5) 28 (7) 34 (3) 35 (5)
Activities of daily living (Katz ADL), 0–6 4 (2) 4 (0) 3 (2) 2 (2) 3 (2) 6 (1) 2 (2) 5 (1)
Depression (CSDD), 0–38, mean (SD) 8 (8) 13 (0) 7 (5) 11 (6) 11 (6) 3 (3) 10 (7) 8 (6)
Resource utilization (RUD) last 30 days (%)
 Hospital admission, geriatric ward 0 0 1 (2) 0 0 0 0 0
 Visit general practitioner 3 (38) 0 29 (50) 42 (81) 9 (21) 4 (100) 7 (44) 1 (8)
 Visit geriatrician 0 0 4 (7) 0 1 (2) 0 0 0
 Visit neurologist 0 0 0 13 (25) 0 0 1 (6) 0
 Visit psychiatrist 0 0 0 0 2 (5) 0 0 0
Neuropsychiatric symptoms (NPI-Q)
 Severity, 0–36, mean, (SD) 11 (7) 12 (0) 10 (7) 11 (6) 12 (8) 5 (5) 8 (4) 8 (5)
Psychotropics, n (%) 4 (50) 1 (100) 1 (47) 33 (64) 24 (57) 2 (50) 14 (88) 7 (58)
 Antipsychotics 0 0 13 (22) 16 (31) 18 (43) 0 7 (44) 2 (17)
 Anxiolytic 0 0 7 (12) 3 (6) 2 (5) 2 (50) 5 (31) 0
 Sedatives 1 (13) 1 (100) 1 (2) 4 (8) 4 (10) 1 (25) 2 (13) 0
 Antidepressants 3 (38) 0 4 (7) 7 (14) 4 (10) 2 (50) 3 (19) 6 (50)
 Anti-dementia medictation 2 (25) 1 (100) 10 (17) 21 (41) 2 (5) 0 5 (31) 2 (17)
  1. Italicized values indicates a positive result, e.g., 0–36
  2. p ≤ 0.05 was regarded as significant; significant p-values are marked in bold
  3. AD Alzheimer’s disease, CCI Charlson comorbidity index, CSDD Cornell scale for depression in dementia, DNOS Dementia not otherwise specified, Katz ADL Katz index of independence in activities of daily living, n Number of participants, NL The Netherlands, NPI-Q Neuropsychiatric inventory questionnaire, QoL-AD Quality of life in AD, RUD Recourse utilization in dementia questionnaire, SMMSE Standardized mini-mental state, UK United Kingdom, VaD Vascular dementia